Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results

CRANBURY, N.J., Sept. 30, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2013. 

Fiscal Year and Recent Highlights

  • Bremelanotide development for Female Sexual Dysfunction (FSD):
  • Completed a successful Phase 2B clinical trial and productive end-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA)
  • Pivotal Phase 3 clinical trials anticipated to initiate patient dosing in the first quarter of calendar year 2014
  • Obesity Collaboration with AstraZeneca:
  • AstraZeneca is evaluating the program and next steps following discontinuation of further development of AZD2820
  • A number of collaboration compounds are in various stages of preclinical testing
  • Intellectual property developments:
  • Two United States patents issued in the melanocortin field in the fiscal year ended June 30, 2013
  • Palatin has advanced its bremelanotide, PL-3994, and new melanocortin peptide patent applications in countries outside the United States
  • Equity financing:
  • On July 3, 2012, Palatin closed on a $35.0 million private placement.  The offering consisted of the sale of 3,873,000 shares of common stock, Series A 2012 warrants to purchase 31,988,151 shares of common stock, and Series B 2012 warrants to purchase 35,488,380 shares of common stock 
  • Net proceeds to Palatin after deducting offering expenses were $34.4 million 
  • Fourth Quarter and Fiscal Year End 2013 Results
    Palatin reported a net loss of $4.7 million, or $(0.04) per basic and diluted share, for the quarter ended June 30, 2013, compared to a net loss of $5.3 million, or $(0.14) per basic and diluted share, for the same period in 2012.The decrease in net loss for the quarter ended June 30, 2013 compared to the net loss for the quarter ended June 30, 2012 was mainly the result of a decrease in costs related to our bremelanotide for FSD program. 

    Palatin's net loss for the year ended June 30, 2013 was $20.9 million, or $(0.21) per basic and diluted share, compared to a net loss of $17.3 million, or $(0.49) per basic and diluted share, for the year ended June 30, 2012. 

    The increase in net loss for the year ended June 30, 2013 compared to the net loss for the year ended June 30, 2012 was mainly attributable to the recognition of a $7.1 million non-cash charge to expense for the increase in the fair value of warrants related to the July 3, 2012 private placement offering partially offset by the decrease in costs related to our bremelanotide for FSD program.

    There were no revenues recorded in the quarter ended June 30, 2013, compared to $11,000 for the same period in 2012.  For the year ended June 30, 2013, revenues were $10,000, compared to $74,000 for year ended June 30, 2012.  Revenue consisted entirely of reimbursement of development costs and per-employee compensation earned at the contractual rate pursuant to Palatin's license agreement with AstraZeneca. 

    Operating Expenses
    For the quarter ended June 30, 2013, total operating expenses were $4.7 million compared to $5.7 million for the comparable quarter of 2012.  For the year ended June 30, 2013, total operating expenses were $15.6 million compared to $18.9 million for the year ended June 30, 2012. The decreases in operating expenses for the respective periods was primarily the result of  a decrease in costs related to our bremelanotide for FSD program, and secondarily as a result of closing our research laboratory operations in connection with the lease expiration of our laboratory facilities in July 2012.

    Cash Position
    Palatin's cash, cash equivalents and short-term investments were $24.4 million as of June 30, 2013, compared to cash and cash equivalents of $3.8 million at June 30, 2012, with current liabilities of $2.1 million as of June 30, 2013 compared to $3.5 million as of June 30, 2012.

    Palatin believes its existing capital resources will be adequate to fund its currently planned operations through at least calendar year 2014. Palatin does not intend to initiate patient enrollment in the Phase 3 studies with bremelanotide for FSD unless it has adequate funds, or commitments for adequate funds, to complete the Phase 3 program.

    Palatin will host a conference call and webcast on October 1, 2013 at 10:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-888-417-8516 (domestic) or 1-719-325-2429 (international), pass code 6711298.  The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at  A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 6711298.  The webcast and telephone replay will be available through October 8, 2013. 

    About Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at

    Forward-looking Statements
    Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

     PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of OperationsQuarter Ended June 30,Year Ended June 30,(Unaudited)(Derived from audited financial

    statements)2013201220132012REVENUES:License and contract

    73,736OPERATING EXPENSES:Research and development

    2,795,0214,130,26410,528,69113,813,376General and administrative

    1,925,0791,571,7515,066,8305,045,741Total operating expenses

    4,720,1005,702,01515,595,52118,859,117Loss from operations

    (4,720,100)(5,690,984)(15,585,160)(18,785,381)OTHER INCOME (EXPENSE):Investment income

    5,7173,90442,73432,133Interest expense

    (3,665)(3,761)(8,411)(10,411)Increase in fair value of warrants

    --(7,069,165)-Gain on disposition of supplies and equipment

    -437,5484,620442,248Total other income (expense), net

    2,052437,691(7,030,222)463,970Loss before income taxes

    (4,718,048)(5,253,293)(22,615,382)(18,321,411)Income tax benefit

    --1,753,2081,068,233NET LOSS

    (17,253,178)Basic and diluted net loss per common share

    (0.49)Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share



     PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Balance Sheets(Derived from audited financial statements)June 30, 2013June 30, 2012ASSETSCurrent assets:Cash and cash equivalents

    3,827,198Short-term investments

    5,249,654-Accounts receivable

    -27,631Restricted cash

    -350,000Prepaid expenses and other current assets

    332,267532,010Total current assets

    24,749,5534,736,839Property and equipment, net

    266,415318,653Other assets

    58,131324,992Total assets

    5,380,484LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Capital lease obligations

    22,277Accounts payable 

    338,726294,894Accrued expenses

    1,701,7272,706,496Accrued compensation

    -433,333Total current liabilities

    2,060,3623,457,000Capital lease obligations 

    -19,909Deferred rent

    35,46072,677Total liabilities

    2,095,8223,549,586Stockholders' equity:Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,697 shares as of June 30, 2013 and 4,997 as of June 30, 2012 

    4750Common stock of $0.01 par value – authorized 300,000,000 shares;issued and outstanding 39,116,948 shares as of June 30, 2013 and 34,900,591 as of June 30, 2012, respectively

    391,169349,006Additional paid-in capital

    282,692,520240,725,127Accumulated deficit 

    (260,105,459)(239,243,285)Total stockholders' equity

    22,978,2771,830,898Total liabilities and stockholders' equity


    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
    3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
    4. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
    5. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
    6. Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
    7. CanCHEW Bio-Technologies, a Medical Marijuana Inc. Product, Dr. George Anastassov Appeared on Small Cap Voice Internet Radio Program To Discuss The CanCHEW Advantage
    8. Drug Discovery Technologies, BCC Research
    9. OrthoAccel Technologies, Inc. Announces Appointment of New Chief Financial Officer
    10. Senesco Technologies, Inc. to Webcast, Live, at on February 7th
    11. Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
    Post Your Comments:
    (Date:6/8/2017)... 8, 2017   Responding to Heath Ledger,s ... death of singer Chris Cornell in May, the ... offers a free online psychiatric drug side ... families about psychotropic drug risks. The father ... from an accidental overdose, has called for tighter rules on ...
    (Date:6/7/2017)... Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), ... location. The Iowa ... 7 cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. A ... "Our new cleanroom will allow ... Iowa patients," said Phil Rielly , ...
    (Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
    Breaking Medicine Technology:
    (Date:6/23/2017)... , ... June 23, 2017 , ... Goodcents Deli Fresh ... The restaurant is located at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st ... of Graham Restaurant Group who owns three other locations in the Topeka and Bonner ...
    (Date:6/23/2017)... ... June 23, 2017 , ... Georgia State ... 18 to 20. , The two-day conference is focused on advancing scientific knowledge ... improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme is ...
    (Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... PureLife ... the endorsed amalgam separator supplier for CDA members. As part of the amalgam separator ... price of $99, saving more than $400 off the retail value. This partnership between ...
    (Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland ... to 3 pm to present to graduate students exciting new and innovative hope research ... project led by The Health Improvement Service of the Western Health & Social Care ...
    (Date:6/23/2017)... ... 2017 , ... All-Star Insurance, a family managed agency that offers insurance management ... announcing the launch of a new charity drive to benefit women in the area ... reveal that an estimated 252, 710 new cases of invasive or high risk breast ...
    Breaking Medicine News(10 mins):